Francesco Recchia

Summary

Country: Italy

Publications

  1. ncbi request reprint Phase II study of interleukin-2 and 13-cis-retinoic acid as maintenance therapy in metastatic colorectal cancer
    Francesco Recchia
    Unita Operativa di Oncologia, Ospedale Civile di Avezzano, Avezzano, Italy
    Cancer Immunol Immunother 56:699-708. 2007
  2. ncbi request reprint Multicenter phase II study of chemo-immunotherapy in the treatment of metastatic renal cell carcinoma
    Francesco Recchia
    Ospedale Civile di Avezzano, Unita Operativa di Oncologia, Monterotondo, Roma
    J Immunother 30:448-54. 2007
  3. doi request reprint Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC
    Francesco Di Costanzo
    Unit of Medical Oncology, Azienda Ospedaliero Universitaria Careggi, Viale Pieraccini 17, 50139 Florence, Italy
    J Natl Cancer Inst 100:388-98. 2008
  4. ncbi request reprint Beta-interferon, retinoids and tamoxifen in metastatic breast cancer: long-term follow-up of a phase II study
    Francesco Recchia
    Oncologia, Ospedale Civile di Avezzano, 67051 Avezzano, AQ, Italy
    Oncol Rep 21:1011-6. 2009
  5. pmc Triple-negative breast cancer: multipronged approach, single-arm pilot phase II study
    Francesco Recchia
    Oncology Unit, Civilian Hospital Avezzano, Italy Carlo Ferri Foundation Monterotondo, Rome, Italy
    Cancer Med 1:89-95. 2012
  6. doi request reprint Chemoembolization of unresectable hepatocellular carcinoma: Decreased toxicity with slow-release doxorubicin‑eluting beads compared with lipiodol
    Francesco Recchia
    Department of Oncology, Civilian Hospital, Avezzano, Italy
    Oncol Rep 27:1377-83. 2012
  7. doi request reprint Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanoma
    Francesco Recchia
    ALS 1 Civilian Hospital, Avezzano, Oncology Division, Monterotondo, Roma
    Anticancer Drugs 19:201-7. 2008
  8. doi request reprint Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck
    Francesco Recchia
    Divisione di Oncologia, ALS 1 Ospedale Civile di Avezzano, Roma, Italy
    J Immunother 31:413-9. 2008
  9. doi request reprint Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer
    Francesco Recchia
    Ospedale Civile di Avezzano, Unita Operativa di Oncologia, Rome, Italy
    Am J Clin Oncol 31:323-8. 2008
  10. ncbi request reprint Maintenance immunotherapy in metastatic breast cancer
    Francesco Recchia
    Ospedale Civile di Avezzano, Unita Operativa di Oncologia
    Oncol Rep 20:1173-9. 2008

Collaborators

Detail Information

Publications33

  1. ncbi request reprint Phase II study of interleukin-2 and 13-cis-retinoic acid as maintenance therapy in metastatic colorectal cancer
    Francesco Recchia
    Unita Operativa di Oncologia, Ospedale Civile di Avezzano, Avezzano, Italy
    Cancer Immunol Immunother 56:699-708. 2007
    ..Secondary endpoint was the evaluation of toxicity, progression-free survival (PFS), and overall survival (OS)...
  2. ncbi request reprint Multicenter phase II study of chemo-immunotherapy in the treatment of metastatic renal cell carcinoma
    Francesco Recchia
    Ospedale Civile di Avezzano, Unita Operativa di Oncologia, Monterotondo, Roma
    J Immunother 30:448-54. 2007
    ..Six cycles of biochemotherapy, being followed by maintenance immunotherapy is well-tolerated and shows significant activity in patients with MRCC...
  3. doi request reprint Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC
    Francesco Di Costanzo
    Unit of Medical Oncology, Azienda Ospedaliero Universitaria Careggi, Viale Pieraccini 17, 50139 Florence, Italy
    J Natl Cancer Inst 100:388-98. 2008
    ..Complete surgical resection of gastric cancer is potentially curative, but long-term survival is poor...
  4. ncbi request reprint Beta-interferon, retinoids and tamoxifen in metastatic breast cancer: long-term follow-up of a phase II study
    Francesco Recchia
    Oncologia, Ospedale Civile di Avezzano, 67051 Avezzano, AQ, Italy
    Oncol Rep 21:1011-6. 2009
    ..9 months, respectively. In conclusion, the study shows that long-term treatment with TAM, beta-IFN and R in MBC is feasible, has moderate toxicity and seems to give a long-term benefit, irrespective of the receptorial status...
  5. pmc Triple-negative breast cancer: multipronged approach, single-arm pilot phase II study
    Francesco Recchia
    Oncology Unit, Civilian Hospital Avezzano, Italy Carlo Ferri Foundation Monterotondo, Rome, Italy
    Cancer Med 1:89-95. 2012
    ..Induction chemotherapy, followed by chemoradiation therapy and HDCT, provides a prolonged disease-free period and a significant increase in overall survival in TNBC, with an acceptable toxicity profile...
  6. doi request reprint Chemoembolization of unresectable hepatocellular carcinoma: Decreased toxicity with slow-release doxorubicin‑eluting beads compared with lipiodol
    Francesco Recchia
    Department of Oncology, Civilian Hospital, Avezzano, Italy
    Oncol Rep 27:1377-83. 2012
    ..001) in DEB-TACE-treated patients compared to TACE-treated patients. DEB-TACE with doxorubicin-loaded DC Beads, a safe and reliable treatment for HCC, leads to decreased toxicity compared to TACE...
  7. doi request reprint Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanoma
    Francesco Recchia
    ALS 1 Civilian Hospital, Avezzano, Oncology Division, Monterotondo, Roma
    Anticancer Drugs 19:201-7. 2008
    ..A regimen of six cycles of biochemotherapy followed by maintenance immunotherapy is well tolerated, and shows significant activity in patients with MM...
  8. doi request reprint Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck
    Francesco Recchia
    Divisione di Oncologia, ALS 1 Ospedale Civile di Avezzano, Roma, Italy
    J Immunother 31:413-9. 2008
    ..Longitudinal changes in lymphocytes, natural killer cells, and VEGF might be useful biomarkers for response and survival...
  9. doi request reprint Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer
    Francesco Recchia
    Ospedale Civile di Avezzano, Unita Operativa di Oncologia, Rome, Italy
    Am J Clin Oncol 31:323-8. 2008
    ....
  10. ncbi request reprint Maintenance immunotherapy in metastatic breast cancer
    Francesco Recchia
    Ospedale Civile di Avezzano, Unita Operativa di Oncologia
    Oncol Rep 20:1173-9. 2008
    ..A randomized trial is warranted...
  11. ncbi request reprint Immunotherapy in patients with less than complete response to chemotherapy
    Francesco Recchia
    Unita Operativa di Oncologia, Ospedale Civile di Avezzano, Italy
    Anticancer Res 29:567-72. 2009
    ..Secondary endpoints were objective response, relapse-free survival (RFS), and overall survival (OS)...
  12. doi request reprint Chemoradioimmunotherapy in locally advanced pancreatic and biliary tree adenocarcinoma: a multicenter phase II study
    Francesco Recchia
    Unita Operativa di Oncologia, Ospedale Civile di Avezzano, Avezzano, Italy
    Pancreas 38:e163-8. 2009
    ..The antitumor activity and toxicity of a multi-step treatment were evaluated in patients with locally advanced, inoperable, or incompletely resected pancreatic (Pa) and biliary tree (Bt) adenocarcinomas (ADKs)...
  13. doi request reprint Maintenance immunotherapy in recurrent ovarian cancer: long term follow-up of a phase II study
    Francesco Recchia
    Ospedale Civile di Avezzano, Unita Operativa di Oncologia, Italy
    Gynecol Oncol 116:202-7. 2010
    ..Here, we report long term follow-up of a group of patients with platinum-sensitive AOC who were treated with IL-2 and RA...
  14. ncbi request reprint Prolonged disease control after myeloablative chemotherapy, autologous transplantation and immunotherapy in high-risk early breast cancer
    Francesco Recchia
    Via Del Castagneto n 15, 67056 Luco dei Marsi AQ, Italy
    Anticancer Res 30:209-15. 2010
    ....
  15. doi request reprint Liposomal pegylated doxorubicin and oxaliplatin as salvage chemotherapy in patients with metastatic gastric cancer treated earlier
    Francesco Recchia
    Ospedale Civile di Avezzano, Unita Operativa di Oncologia, Italy
    Anticancer Drugs 21:559-64. 2010
    ..PLD and LOHP is an active regimen, able to give palliation in a substantial percentage of MCG patients who have been pretreated with taxanes...
  16. ncbi request reprint Premenopausal hormone-responsive breast cancer with extensive axillary nodes involvement: total estrogen blockade and chemotherapy
    Francesco Recchia
    Civilian Hospital, Oncology Department, Avezzano, Italy
    Anticancer Res 31:671-6. 2011
    ..The role of adjuvant chemotherapy (CT) and hormonal therapy have not yet been established in these patients...
  17. ncbi request reprint A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer
    Francesco Recchia
    Unita Operativa di Oncologia, Ospedale Civile di Avezzano, AQ, Italy
    Gynecol Oncol 106:164-9. 2007
    ..This phase II study investigated the safety and activity of PLD and LOHP used in combination to treat ROC...
  18. ncbi request reprint Chemoimmunotherapy in the treatment of metastatic gastric cancer
    Francesco Recchia
    Civilian Hospital, Oncology Unit, Avezzano, Carlo Ferri Foundation, Monterotondo, Rome, and Clinical Epidemiology, University of L Aquila, Italy
    Anticancer Drugs 18:597-604. 2007
    ....
  19. ncbi request reprint Paclitaxel plus gemcitabine in advanced non-small cell lung cancer patients with low performance status
    Francesco Recchia
    Ospedale Civile di Avezzano, Monterotondo Roma, Italy
    Anticancer Res 25:409-14. 2005
    ..The aim was to determine the efficacy and safety of a platinum-free regimen combining gemcitabine and paclitaxel for the treatment of patients with advanced non-small cell lung cancer (NSCLC) and a low performance status (PS)...
  20. ncbi request reprint Phase II randomized study of interleukin-2 with or without 13-cis retinoic acid as maintenance therapy in patients with advanced cancer responsive to chemotherapy
    Francesco Recchia
    Unita Operativa di Oncologia, Ospedale Civile di Avezzano, Italy
    Anticancer Res 25:3149-57. 2005
    ..The aim of this phase II randomized study was to verify the role of RA in this drug combination...
  21. ncbi request reprint Interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced ovarian cancer
    Francesco Recchia
    Ospedale Civile di Avezzano, Unita Operativa di Oncologia, Rome, Italy
    Int J Oncol 27:1039-46. 2005
    ..These preliminary data show that, after chemotherapy for AOC, the administration of low-dose subcutaneous IL-2 and oral RA is feasible, has low toxicity, is cost-effective and improves both PFS and OS...
  22. ncbi request reprint Multicenter phase 2 study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced non-small-cell lung cancer
    Francesco Recchia
    Unita Operativa di Oncologia, Ospedale Civile di Avezzano, Avezzano, Italy
    J Immunother 29:87-94. 2006
    ....
  23. ncbi request reprint Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma
    Francesco Recchia
    Unita Operativa di Oncologia, Ospedale Civile di Avezzano, Avezzano, Italy
    Cancer 106:514-23. 2006
    ....
  24. ncbi request reprint Cardiac metastases in malignant fibrous histiocytoma. A case report
    Francesco Recchia
    Unita Operativa di Oncologia, Ospedale Civile di Avezzano, AQ, Italy
    Tumori 92:76-8. 2006
    ..The response continued to improve with immunotherapy. The patient returned to normal physical activity. He died four years later due to a ventricular arrhythmia...
  25. ncbi request reprint Dose-finding study of docetaxel added to ifosfamide and cisplatin followed by concomitant capecitabine and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck
    Francesco Recchia
    ALS 1 Ospedale Civile di Avezzano, Divisione di Oncologia, Monterotondo, Roma, Italy
    Anticancer Res 26:2317-24. 2006
    ....
  26. ncbi request reprint Oxaliplatin fractionated over two days with bimonthly leucovorin and 5-fluorouracil in metastatic colorectal cancer
    Francesco Recchia
    Unita operative di Oncologia, Ospedale Civile di Avezzano, Italy
    Anticancer Res 24:1935-40. 2004
    ..To evaluate the efficacy and safety of oxaliplatin (L-OHP) fractionated over two days with bimonthly 5-fluorouracil (5-FU) and leucovorin (LV), as first-line treatment of metastatic colorectal cancer (MCC) patients...
  27. ncbi request reprint Phase I study of liposomal doxorubicin and oxaliplatin as salvage chemotherapy in advanced ovarian cancer
    Francesco Recchia
    ALS 2 Ospedale Civile di Avezzano, Division of Oncology, Monterotondo, Roma, Italy
    Anticancer Drugs 14:633-8. 2003
    ..Promising anti-tumor activity was observed...
  28. ncbi request reprint Gemcitabine, ifosfamide and vinorelbine in advanced non-small cell lung cancer: a phase II study
    Francesco Recchia
    Unita Operativa di Oncologia, Ospedale Civile di Avezzano, Universita degli Studi di L Aquila, Italy
    Anticancer Res 22:1321-8. 2002
    ..The objective of this phase II study was to determine the activity and toxicity of gemcitabine, ifosfamide and vinorelbine, in the treatment of patients with advanced non-small cell lung cancer (NSCLC)...
  29. ncbi request reprint Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: a phase II pilot study
    Francesco Recchia
    Ospedale Civile di Avezzano, Divisione di Oncologia, Fondazione Carlo Ferri, Monterotondo, Roma, Italy
    Anticancer Drugs 13:417-24. 2002
    ..No unexpected adverse events were reported. These data show that the addition of goserelin to adjuvant therapy of premenopausal patients with early breast cancer is well tolerated and protects long-term ovarian function...
  30. ncbi request reprint Interleukin-2 and 13-cis retinoic acid in the treatment of minimal residual disease: a phase II study
    Francesco Recchia
    Unita Operativa di Oncologia, Ospedale Civile di Avezzano, Italy
    Int J Oncol 20:1275-82. 2002
    ..A sustained increase in the immunological parameters known to be prognostically relevant was observed and a clear benefit on tumor response from immunotherapy was obtained in 7.5% of patients...
  31. doi request reprint Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective survey
    Lazzaro Repetto
    Oncology Department, Istituto Nazionale di Riposo e Cura per Anziani, INRCA IRCCS, Via Cassia 1167, Rome 00189, Italy
    Crit Rev Oncol Hematol 72:170-9. 2009
    ..To evaluate the frequency of chemotherapy-induced myelotoxicity in cancer patients, the related treatment (G-CSF, rHuEPO), and the occurrence of chemotherapy dose reductions, delays or discontinuations...
  32. ncbi request reprint High-dose carboplatin, cyclophosphamide, etoposide with hematological growth factors, without stem cell support in patients with advanced cancer
    Francesco Recchia
    UnitĂ  operative di Oncologia Ospedale Civile di Avezzano, Italy
    Anticancer Res 23:4141-7. 2003
    ..The aim of this phase II study was to evaluate the activity and toxicity of HDCT with CB, CT and VP administered with growth factors, without PBPC in a group of patients with advanced solid tumors...